

REMARKS

Objections to the specification

Examiner has noted that there is a disparity in the sequence numbering between SEQ ID NO:22 as represented on page 57 and SEQ ID NO: 22 as provided in the sequence listing. This discrepancy relates it to be a tyrosine substitution at position 668. Applicants note that the sequence has presented on page 57 (SEQ ID NO:22) is identical in sequence to sequence ID 22 as indicated in the sequence listing. However it can be seen that the numbering of the tyrosine to phenylalanine substitution underlined at position 668 one page 57 is incorrect, and should in fact be position 665.

Applicants have presented an amendment to the specification changing the "668" to "665". It is readily apparent to a person of ordinary skill in the art looking at SEQ ID:22 on page 57, that a gap of 3 spaces exists prior to the start of the sequence information. The automated numbering system used by the program included the 3 blank gap in assigning the numbering scheme. Counting out to amino acid 665 reveals the correct numbering. The sequence ID listing for SEQ ID NO:22 is correct.

Rejection under 35 USC section 112, first paragraph

Claims 34 and 46 were rejected under 35 USC section 112, first paragraph as not being enabled by the specification. The rejection is avoided by the amendments canceling claims 34 and 46.

Rejection under 35 USC section 103

Claims 34 and 35 were rejected under 35 USC section 103 as being obvious over Gelfand et al. the rejection is avoided by the amendments canceling claims 34 and 35.